Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Targeting PI3Kδ Function For Amelioration of Murine Chronic Graft-Versus-Host Disease.

Paz K, Flynn R, Du J, Tannheimer S, Johnson AJ, Dong S, Stark AK, Okkenhaug K, Panoskaltsis-Mortari A, Sage PT, Sharpe AH, Luznik L, Ritz J, Soiffer RJ, Cutler CS, Koreth J, Antin JH, Miklos DB, MacDonald KP, Hill GR, Maillard I, Serody JS, Murphy WJ, Munn DH, Feser C, Zaiken M, Vanhaesebroeck B, Turka LA, Byrd JC, Blazar BR.

Am J Transplant. 2019 Feb 12. doi: 10.1111/ajt.15305. [Epub ahead of print]

PMID:
30748099
2.

Evaluation of 72Se/72As generator and production of 72Se for supplying 72As as a potential PET imaging radionuclide.

Feng Y, Phipps MD, Phelps TE, Okoye NC, Baumeister JE, Wycoff DE, Dorman EF, Wooten AL, Vlasenko V, Berendzen AF, Wilbur DS, Hoffman TJ, Cutler CS, Ketring AR, Jurisson SS.

Appl Radiat Isot. 2019 Jan;143:113-122. doi: 10.1016/j.apradiso.2018.10.026. Epub 2018 Oct 30.

PMID:
30408634
3.

Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.

Paz K, Flynn R, Du J, Qi J, Luznik L, Maillard I, MacDonald KP, Hill GR, Serody JS, Murphy WJ, Sage PT, Sharpe AH, Miklos D, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Bradner JE, Melnick AM, Blazar BR.

Blood. 2019 Jan 3;133(1):94-99. doi: 10.1182/blood-2018-03-839993. Epub 2018 Oct 2.

PMID:
30279226
4.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, Newell LF, Jagasia MH, Pusic I, Wood WA, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera YA, Ferrara JLM, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar BR, Weisdorf DJ, MacMillan ML.

Blood Adv. 2018 Aug 14;2(15):1882-1888. doi: 10.1182/bloodadvances.2018017343.

5.

A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801.

Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolaños-Meade J, Sarantopoulos S, Alousi AM, Abhyankar S, Waller EK, Mendizabal A, Zhu J, O'Brien KA, Lazaryan A, Wu J, Nemecek ER, Pavletic SZ, Cutler CS, Horowitz MM, Arora M; BMT CTN.

Haematologica. 2018 Nov;103(11):1915-1924. doi: 10.3324/haematol.2018.195123. Epub 2018 Jun 28.

6.

Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors.

Hanna GJ, Kofman ER, Shazib MA, Woo SB, Reardon B, Treister NS, Haddad RI, Cutler CS, Antin JH, Van Allen EM, Uppaluri R, Soiffer RJ.

Oral Oncol. 2018 Jun;81:1-9. doi: 10.1016/j.oraloncology.2018.04.007. Epub 2018 Apr 10.

PMID:
29884406
7.

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.

Kumar AJ, Kim S, Hemmer MT, Arora M, Spellman SR, Pidala JA, Couriel DR, Alousi AM, Aljurf MD, Cahn JY, Cairo MS, Cutler CS, Farhan S, Gergis U, Hale GA, Hashmi SK, Inamoto Y, Kamble RT, Kharfan-Dabaja MA, MacMillan ML, Marks DI, Nakasone H, Norkin M, Qayed M, Ringden O, Schouten HC, Schultz KR, Solh MM, Teshima T, Urbano-Ispizua A, Verdonck LF, Gale RP, Hamilton BK, Majhail NS, Loren AW.

Blood Adv. 2018 May 8;2(9):1022-1031. doi: 10.1182/bloodadvances.2017013052. Erratum in: Blood Adv. 2018 Jun 12;2(11):1294.

8.

Letter to the Editor: International Consensus Radiochemistry Nomenclature Guidelines.

Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.

Curr Radiopharm. 2018;11(1):73-75. doi: 10.2174/187447101101180404111248. No abstract available.

PMID:
29624156
9.

A trithiol bifunctional chelate for 72,77As: A matched pair theranostic complex with high in vivo stability.

Feng Y, DeGraffenreid AJ, Phipps MD, Rold TL, Okoye NC, Gallazzi FA, Barnes CL, Cutler CS, Ketring AR, Hoffman TJ, Jurisson SS.

Nucl Med Biol. 2018 Jun;61:1-10. doi: 10.1016/j.nucmedbio.2018.03.001. Epub 2018 Mar 10.

PMID:
29571038
10.

A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.

Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P, Ritz J, Nikiforow S, Glotzbecker BE, Nageshwar P, Soiffer RJ, Antin JH, Cutler CS.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1733-1740. doi: 10.1016/j.bbmt.2018.03.011. Epub 2018 Mar 16.

PMID:
29555313
11.

International Consensus Radiochemistry Nomenclature Guidelines.

Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.

Nuklearmedizin. 2018 Feb;57(1):40-41. doi: 10.1055/s-0038-1636563. Epub 2018 Feb 21. No abstract available.

PMID:
29536500
12.

Open letter to journal editors on: international consensus radiochemistry nomenclature guidelines.

Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.

Am J Nucl Med Mol Imaging. 2018 Feb 5;8(1):70-72. eCollection 2018. No abstract available.

13.

Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines.

Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.

Nucl Med Commun. 2018 Mar;39(3):193-195. doi: 10.1097/MNM.0000000000000799. No abstract available.

PMID:
29438216
14.

α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.

Magenau JM, Goldstein SC, Peltier D, Soiffer RJ, Braun T, Pawarode A, Riwes MM, Kennel M, Antin JH, Cutler CS, Ho VT, Alyea EP 3rd, Parkin BL, Yanik GA, Choi SW, Lewis EC, Dinarello CA, Koreth J, Reddy P.

Blood. 2018 Mar 22;131(12):1372-1379. doi: 10.1182/blood-2017-11-815746. Epub 2018 Feb 2.

PMID:
29437593
15.

Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines.

Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.

Ann Nucl Med. 2018 Apr;32(3):236-238. doi: 10.1007/s12149-018-1238-z. Epub 2018 Feb 8. No abstract available.

16.

Open letter to journal editors on: International consensus radiochemistry nomenclature guidelines.

Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.

J Labelled Comp Radiopharm. 2018 Apr;61(4):402-404. doi: 10.1002/jlcr.3604. No abstract available.

PMID:
29331022
17.

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results.

Koreth J, Kim HT, Lange PB, Poryanda SJ, Reynolds CG, Rai SC, Armand P, Cutler CS, Ho VT, Glotzbecker B, Yusuf R, Nikiforow S, Chen YB, Dey B, McMasters M, Ritz J, Blazar BR, Soiffer RJ, Antin JH, Alyea EP 3rd.

Haematologica. 2018 Mar;103(3):522-530. doi: 10.3324/haematol.2017.176859. Epub 2018 Jan 11.

18.

Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease.

DeFilipp Z, Nazarian RM, El-Jawahri A, Li S, Brown J, Del Rio C, Smith M, Valles B, Ballen KK, McAfee SL, Rosenblatt J, Antin JH, Cutler CS, Chen YB.

Blood Adv. 2017 Oct 5;1(22):1919-1922. doi: 10.1182/bloodadvances.2017011239. eCollection 2017 Oct 10.

19.

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P.

Biol Blood Marrow Transplant. 2018 Mar;24(3):514-520. doi: 10.1016/j.bbmt.2017.11.023. Epub 2017 Nov 28.

PMID:
29196080
20.

Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease.

Wang KS, Kim HT, Nikiforow S, Heubeck AT, Ho VT, Koreth J, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Cutler CS, Ritz J.

Blood. 2017 Dec 28;130(26):2889-2899. doi: 10.1182/blood-2017-08-801001. Epub 2017 Nov 14.

21.

Consensus nomenclature rules for radiopharmaceutical chemistry - Setting the record straight.

Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.

Nucl Med Biol. 2017 Dec;55:v-xi. doi: 10.1016/j.nucmedbio.2017.09.004. Epub 2017 Oct 2. Review.

PMID:
29074076
22.

Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402.

Turcotte LM, DeFor TE, Newell LF, Cutler CS, Verneris MR, Wu J, Howard A, MacMillan ML, Antin JH, Vercellotti GM, Slungaard A, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A, Holtan SG.

Bone Marrow Transplant. 2018 Jan;53(1):64-68. doi: 10.1038/bmt.2017.236. Epub 2017 Oct 23.

23.

Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.

Geyer MB, Manjunath SH, Evans AG, Park JH, Davila ML, Cutler CS, Wang X, Wang Y, Senechal B, Rivière I, Sadelain M, Liesveld JL, Brentjens RJ.

Leuk Lymphoma. 2018 Jul;59(7):1717-1721. doi: 10.1080/10428194.2017.1390237. Epub 2017 Oct 18. No abstract available.

PMID:
29043880
24.

Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes.

Hamilton BK, Rybicki L, Arai S, Arora M, Cutler CS, Flowers MED, Jagasia M, Martin PJ, Palmer J, Pidala J, Majhail NS, Lee SJ, Khera N.

Biol Blood Marrow Transplant. 2018 Feb;24(2):393-399. doi: 10.1016/j.bbmt.2017.10.009. Epub 2017 Oct 12.

25.

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S.

Blood. 2017 Nov 23;130(21):2243-2250. doi: 10.1182/blood-2017-07-793786. Epub 2017 Sep 18.

26.

Radiometric evaluation of diglycolamide resins for the chromatographic separation of actinium from fission product lanthanides.

Radchenko V, Mastren T, Meyer CAL, Ivanov AS, Bryantsev VS, Copping R, Denton D, Engle JW, Griswold JR, Murphy K, Wilson JJ, Owens A, Wyant L, Birnbaum ER, Fitzsimmons J, Medvedev D, Cutler CS, Mausner LF, Nortier MF, John KD, Mirzadeh S, Fassbender ME.

Talanta. 2017 Dec 1;175:318-324. doi: 10.1016/j.talanta.2017.07.057. Epub 2017 Jul 20.

PMID:
28841997
27.

An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.

Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W, Liu L, Bakoyannis G, Jiang D, Chu HW, Lobera M, Yang J, Wilkes DS, Du J, Gartlan K, Hill GR, MacDonald KP, Espada EL, Blanco P, Serody JS, Koreth J, Cutler CS, Antin JH, Soiffer RJ, Ritz J, Paczesny S, Blazar BR.

JCI Insight. 2017 Jun 15;2(12). pii: 92111. doi: 10.1172/jci.insight.92111. [Epub ahead of print]

28.

An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.

Martin PJ, Storer BE, Inamoto Y, Flowers MED, Carpenter PA, Pidala J, Palmer J, Arora M, Jagasia M, Arai S, Cutler CS, Lee SJ.

Blood. 2017 Jul 20;130(3):360-367. doi: 10.1182/blood-2017-03-775767. Epub 2017 May 11.

29.

Mangiferin functionalized radioactive gold nanoparticles (MGF-198AuNPs) in prostate tumor therapy: green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy.

Al-Yasiri AY, Khoobchandani M, Cutler CS, Watkinson L, Carmack T, Smith CJ, Kuchuk M, Loyalka SK, Lugão AB, Katti KV.

Dalton Trans. 2017 Oct 31;46(42):14561-14571. doi: 10.1039/c7dt00383h.

PMID:
28440368
30.

Proton-induced production and radiochemical isolation of 44Ti from scandium metal targets for 44Ti/44Sc generator development.

Radchenko V, Engle JW, Medvedev DG, Maassen JM, Naranjo CM, Unc GA, Meyer CAL, Mastren T, Brugh M, Mausner L, Cutler CS, Birnbaum ER, John KD, Nortier FM, Fassbender ME.

Nucl Med Biol. 2017 Jul;50:25-32. doi: 10.1016/j.nucmedbio.2017.03.006. Epub 2017 Apr 7.

PMID:
28432915
31.

Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.

Du J, Paz K, Flynn R, Vulic A, Robinson TM, Lineburg KE, Alexander KA, Meng J, Roy S, Panoskaltsis-Mortari A, Loschi M, Hill GR, Serody JS, Maillard I, Miklos D, Koreth J, Cutler CS, Antin JH, Ritz J, MacDonald KP, Schacker TW, Luznik L, Blazar BR.

Blood. 2017 May 4;129(18):2570-2580. doi: 10.1182/blood-2017-01-758854. Epub 2017 Mar 2.

32.

PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.

Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, Sando Y, Yagita H, Koreth J, Kim HT, Alyea EP, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Maeda Y, Tanimoto M, Ritz J, Matsuoka KI.

Blood. 2017 Apr 13;129(15):2186-2197. doi: 10.1182/blood-2016-09-741629. Epub 2017 Feb 1.

33.

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts.

Brunstein CG, Cutler CS, DeFor TE, Kim H, Bejanyan N, Garfall A, Verneris MR, Chen YB, Warlick ED, Spitzer T, Miller JS, Antin JH, Weisdorf DJ, Soiffer R, Wagner JE, Ballen KK.

Biol Blood Marrow Transplant. 2017 Jan;23(1):126-133. doi: 10.1016/j.bbmt.2016.10.018. Epub 2016 Oct 29.

34.

GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.

Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS.

Bone Marrow Transplant. 2017 Mar;52(3):400-408. doi: 10.1038/bmt.2016.265. Epub 2016 Dec 12.

35.

Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients.

Nikiforow S, Li S, Snow K, Liney D, Kao GS, Haspel R, Shpall EJ, Glotzbecker B, Sica RA, Armand P, Koreth J, Ho VT, Alyea EP 3rd, Ritz J, Soiffer RJ, Antin JH, Dey B, McAfee S, Chen YB, Spitzer T, Avigan D, Cutler CS, Ballen K.

Cytotherapy. 2017 Feb;19(2):272-284. doi: 10.1016/j.jcyt.2016.10.016. Epub 2016 Dec 9.

PMID:
27939176
36.

Mechanistic approaches for the prevention and treatment of chronic GVHD.

Cutler CS, Koreth J, Ritz J.

Blood. 2017 Jan 5;129(1):22-29. doi: 10.1182/blood-2016-08-686659. Epub 2016 Nov 7. Review.

37.

Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.

Brunner AM, Li S, Fathi AT, Wadleigh M, Ho VT, Collier K, Connolly C, Ballen KK, Cutler CS, Dey BR, El-Jawahri A, Nikiforow S, McAfee SL, Koreth J, Deangelo DJ, Alyea EP, Antin JH, Spitzer TR, Stone RM, Soiffer RJ, Chen YB.

Br J Haematol. 2016 Nov;175(3):496-504. doi: 10.1111/bjh.14260. Epub 2016 Jul 19.

38.

Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.

Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, Alyea EP, Carlton VE, Chen YB, Cutler CS, Ho VT, Koreth J, Kotwaliwale C, Nikiforow S, Ritz J, Rodig SJ, Soiffer RJ, Antin JH, Armand P.

Br J Haematol. 2016 Dec;175(5):841-850. doi: 10.1111/bjh.14311. Epub 2016 Oct 6.

39.

Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

Holtan SG, Khera N, Levine JE, Chai X, Storer B, Liu HD, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Flowers MED, Cutler CS, Lukez A, Arai S, Lazaryan A, Newell LF, Krupski C, Jagasia MH, Pusic I, Wood W, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Watanaboonyongcharoen P, Efebera YA, Ferrara JLM, Panoskaltsis-Mortari A, Weisdorf D, Lee SJ, Pidala J.

Blood. 2016 Nov 10;128(19):2350-2358. doi: 10.1182/blood-2015-09-669846. Epub 2016 Sep 13.

40.

A novel TERC CR4/CR5 domain mutation causes telomere disease via decreased TERT binding.

Boyraz B, Bellomo CM, Fleming MD, Cutler CS, Agarwal S.

Blood. 2016 Oct 20;128(16):2089-2092. doi: 10.1182/blood-2016-04-710160. Epub 2016 Sep 1. No abstract available.

41.

Dithiol Aryl Arsenic Compounds as Potential Diagnostic and Therapeutic Radiopharmaceuticals.

DeGraffenreid AJ, Feng Y, Wycoff DE, Morrow R, Phipps MD, Cutler CS, Ketring AR, Barnes CL, Jurisson SS.

Inorg Chem. 2016 Aug 15;55(16):8091-8. doi: 10.1021/acs.inorgchem.6b01175. Epub 2016 Jul 25.

PMID:
27453472
42.

Deuteron irradiation of W and WO3 for production of high specific activity (186)Re: Challenges associated with thick target preparation.

Balkin ER, Gagnon K, Strong KT, Smith BE, Dorman EF, Emery RC, Pauzauskie PJ, Fassbender ME, Cutler CS, Ketring AR, Jurisson SS, Wilbur DS.

Appl Radiat Isot. 2016 Sep;115:197-207. doi: 10.1016/j.apradiso.2016.06.021. Epub 2016 Jun 28.

PMID:
27423020
43.

Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner.

McDonald-Hyman C, Flynn R, Panoskaltsis-Mortari A, Peterson N, MacDonald KP, Hill GR, Luznik L, Serody JS, Murphy WJ, Maillard I, Munn DH, Turka LA, Koreth J, Cutler CS, Soiffer RJ, Antin JH, Ritz J, Blazar BR.

Blood. 2016 Aug 18;128(7):1013-7. doi: 10.1182/blood-2016-05-715896. Epub 2016 Jul 6.

44.

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.

Nikiforow S, Kim HT, Daley H, Reynolds C, Jones KT, Armand P, Ho VT, Alyea EP 3rd, Cutler CS, Ritz J, Antin JH, Soiffer RJ, Koreth J.

Haematologica. 2016 Oct;101(10):1251-1259. Epub 2016 Jun 27.

45.

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.

Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W.

Cancer. 2016 Oct;122(19):3005-3014. doi: 10.1002/cncr.30140. Epub 2016 Jun 17.

46.

Accelerator-based production of the (99m)Tc-(186)Re diagnostic-therapeutic pair using metal disulfide targets (MoS2, WS2, OsS2).

Gott MD, Hayes CR, Wycoff DE, Balkin ER, Smith BE, Pauzauskie PJ, Fassbender ME, Cutler CS, Ketring AR, Wilbur DS, Jurisson SS.

Appl Radiat Isot. 2016 Aug;114:159-66. doi: 10.1016/j.apradiso.2016.05.024. Epub 2016 May 19.

PMID:
27236832
47.

Trithiols and their arsenic compounds for potential use in diagnostic and therapeutic radiopharmaceuticals.

DeGraffenreid AJ, Feng Y, Barnes CL, Ketring AR, Cutler CS, Jurisson SS.

Nucl Med Biol. 2016 May;43(5):288-95. doi: 10.1016/j.nucmedbio.2016.01.005. Epub 2016 Feb 14.

48.

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.

Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, Dusenbury K, Whangbo J, Nikiforow S, Alyea EP 3rd, Armand P, Cutler CS, Ho VT, Chen YB, Avigan D, Blazar BR, Antin JH, Ritz J, Soiffer RJ.

Blood. 2016 Jul 7;128(1):130-7. doi: 10.1182/blood-2016-02-702852. Epub 2016 Apr 12.

49.

Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?

El-Jawahri A, Kim HT, Steensma DP, Cronin AM, Stone RM, Watts CD, Chen YB, Cutler CS, Soiffer RJ, Abel GA.

Bone Marrow Transplant. 2016 Aug;51(8):1121-6. doi: 10.1038/bmt.2016.40. Epub 2016 Mar 21.

PMID:
26999469
50.

Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.

Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, Vulic A, Luznik L, MacDonald KK, Hill GR, Nyuydzefe MS, Weiss JM, Chen W, Trzeciak A, Serody JS, Aguilar EG, Murphy WJ, Maillard I, Munn D, Koreth J, Cutler CS, Antin JH, Ritz J, Waksal SD, Zanin-Zhorov A, Blazar BR.

Blood. 2016 Apr 28;127(17):2144-54. doi: 10.1182/blood-2015-10-678706. Epub 2016 Mar 16.

Supplemental Content

Loading ...
Support Center